August 28, 2017 – By Henry Gaston
Sentiment for Chemed Corp (NYSE:CHE)
Chemed Corp (NYSE:CHE) institutional sentiment increased to 1.05 in Q4 2016. Its up 0.23, from 0.82 in 2016Q3. The ratio is more positive, as 105 funds opened new or increased equity positions, while 100 sold and decreased positions in Chemed Corp. The funds in our partner’s database now possess: 16.12 million shares, up from 15.54 million shares in 2016Q3. Also, the number of funds holding Chemed Corp in their top 10 equity positions increased from 1 to 2 for an increase of 1. Sold All: 19 Reduced: 81 Increased: 74 New Position: 31.
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The company has market cap of $3.09 billion. The Firm operates through two divisions: the VITAS segment and the Roto-Rooter segment (Roto-Rooter). It has a 48.46 P/E ratio. The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
About 58,043 shares traded. Chemed Corporation (NYSE:CHE) has risen 54.48% since August 28, 2016 and is uptrending. It has outperformed by 37.78% the S&P500.
Van Berkom & Associates Inc. holds 3% of its portfolio in Chemed Corporation for 465,276 shares. Riverbridge Partners Llc owns 764,047 shares or 2.56% of their US portfolio. Moreover, Cardinal Capital Management Llc Ct has 1.59% invested in the company for 231,137 shares. The Pennsylvania-based Copeland Capital Management Llc has invested 1.4% in the stock. Eagle Boston Investment Management Inc, a Massachusetts-based fund reported 64,004 shares.#img1#
Since January 1, 0001, it had 1 insider buy, and 4 selling transactions for $2.56 million activity.
Chemed Corporation (NYSE:CHE) Ratings Coverage
Ratings analysis reveals 33% of Chemed’s analysts are positive. Out of 3 Wall Street analysts rating Chemed, 1 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $129 while the high is $20900. The stock’s average target of $177 is -8.15% below today’s ($192.71) share price. CHE was included in 12 notes of analysts from July 27, 2015. RBC Capital Markets maintained it with “Hold” rating and $20900 target in Sunday, July 30 report. As per Monday, October 26, the company rating was maintained by Oppenheimer. The stock of Chemed Corporation (NYSE:CHE) has “Outperform” rating given on Tuesday, September 22 by Oppenheimer. The firm earned “Sector Perform” rating on Monday, July 27 by RBC Capital Markets. Oppenheimer maintained the shares of CHE in report on Tuesday, July 25 with “Buy” rating. RBC Capital Markets maintained the shares of CHE in report on Tuesday, May 30 with “Hold” rating. The company was maintained on Monday, May 2 by RBC Capital Markets. RBC Capital Markets maintained Chemed Corporation (NYSE:CHE) rating on Wednesday, July 5. RBC Capital Markets has “Hold” rating and $20800 target. RBC Capital Markets maintained Chemed Corporation (NYSE:CHE) rating on Monday, October 26. RBC Capital Markets has “Sector Perform” rating and $154 target. The stock of Chemed Corporation (NYSE:CHE) earned “Sector Perform” rating by RBC Capital Markets on Tuesday, November 1.
More notable recent Chemed Corporation (NYSE:CHE) news were published by: Businesswire.com which released: “Chemed Reports Second-Quarter 2017 Results” on July 25, 2017, also Nasdaq.com with their article: “Why Is Chemed (CHE) Down 7.8% Since the Last Earnings Report?” published on August 25, 2017, Businesswire.com published: “Chemed Corporation Increases Quarterly Dividend 7.7%” on August 04, 2017. More interesting news about Chemed Corporation (NYSE:CHE) were released by: Zacks.com and their article: “Here’s Why Chemed (CHE) is a Suitable Growth Pick for Now” published on August 28, 2017 as well as Seekingalpha.com‘s news article titled: “Chemed: Hospice And…Plumbing?” with publication date: April 04, 2017.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.